{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:15Z","timestamp":1791876915987,"version":"4.3.4"},"reference-count":33,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed\/refractory mantle cell lymphoma (R\/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R\/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R\/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell\u2013associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with \u22653 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015014","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:57:00Z","timestamp":1753390620000},"page":"5382-5396","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"first","affiliation":[{"name":"1The University of Kansas Cancer Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-3274","authenticated-orcid":false,"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"2City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, and Blood and Marrow Transplant Program and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Huan","family":"Hu","sequence":"additional","affiliation":[{"name":"4Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[{"name":"5The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"6Fred Hutchinson Cancer Center and University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"7Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-187X","authenticated-orcid":false,"given":"James","family":"Gerson","sequence":"additional","affiliation":[{"name":"8The University of Vermont Medical Center, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"9Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"2City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"10The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0575","authenticated-orcid":false,"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, and Blood and Marrow Transplant Program and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bye","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, and Blood and Marrow Transplant Program and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"11Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[{"name":"12Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-4497","authenticated-orcid":false,"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[{"name":"13Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4461","authenticated-orcid":false,"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"14Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"15The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"10The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-004X","authenticated-orcid":false,"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[{"name":"16Division of Pediatric Hematology\/Oncology\/Blood and Marrow Transplant, Department of Medicine, Department of Pediatrics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Logan","sequence":"additional","affiliation":[{"name":"17Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7481-9550","authenticated-orcid":false,"given":"Ana","family":"Nunes","sequence":"additional","affiliation":[{"name":"4Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3299-151X","authenticated-orcid":false,"given":"David","family":"Dalton","sequence":"additional","affiliation":[{"name":"4Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Kloos","sequence":"additional","affiliation":[{"name":"4Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"name":"4Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[{"name":"4Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, and Blood and Marrow Transplant Program and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"2City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"4","key":"2025102811214907200_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2025102811214907200_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"16","key":"2025102811214907200_bib3","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"2025102811214907200_bib4","doi-asserted-by":"crossref","first-page":"20406207221080738","DOI":"10.1177\/20406207221080738","article-title":"Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)","volume":"13","author":"Tbakhi","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2025102811214907200_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2017.10.004","article-title":"A systematic review of treatments of relapsed\/refractory mantle cell lymphoma","volume":"18","author":"Parrott","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025102811214907200_bib6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025102811214907200_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/jpm12030376","article-title":"Relapsed\/refractory mantle cell lymphoma: beyond BTK inhibitors","volume":"12","author":"Burkart","year":"2022","journal-title":"J Pers Med"},{"issue":"6","key":"2025102811214907200_bib8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"2025102811214907200_bib9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025102811214907200_bib10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \"real world\" study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"2025102811214907200_bib11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2022","journal-title":"Br J Haematol"},{"issue":"14","key":"2025102811214907200_bib12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025102811214907200_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2023-174273","article-title":"Outcomes of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study [abstract]","volume":"142","author":"Goy","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025102811214907200_bib14","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"2025102811214907200_bib15","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025102811214907200_bib16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025102811214907200_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025102811214907200_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025102811214907200_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025102811214907200_bib20","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/hem3.29","article-title":"High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"2025102811214907200_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ajh.27198","article-title":"Improving the safety of CAR-T-cell therapy: the risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy","volume":"99","author":"Qian","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"2025102811214907200_bib22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s11912-022-01286-0","article-title":"BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-finding a dancing partner","volume":"24","author":"Munoz","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"suppl 1","key":"2025102811214907200_bib23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood-2024-198021","article-title":"Primary analysis of ZUMA-2 cohort 3: brexucabtagene autoleucel (Brexu-Cel) in patients (Pts) with relapsed\/refractory mantle cell lymphoma (R\/R MCL) who were naive to Bruton tyrosine kinase inhibitors (BTKi) [abstract]","volume":"144","author":"van Meerten","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025102811214907200_bib24","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2025102811214907200_bib25","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2025102811214907200_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0000000000000267","article-title":"Functionally defective T cells after chemotherapy of B-cell malignancies can be activated by the tetravalent bispecific CD19\/CD3 antibody AFM11","volume":"42","author":"Duell","year":"2019","journal-title":"J Immunother"},{"issue":"2","key":"2025102811214907200_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025102811214907200_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological malignancies","volume":"57","author":"Gafter-Gvili","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2025102811214907200_bib29","author":"National Comprehensive Cancer Network","year":"2023"},{"issue":"9","key":"2025102811214907200_bib30","first-page":"720","article-title":"American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular Therapies in mantle cell lymphoma","volume":"27","author":"Munshi","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2025102811214907200_bib31","first-page":"594","article-title":"Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"2025102811214907200_bib32","volume-title":"TECARTUS (brexucabtagene autoleucel). Package insert","year":"2021"},{"issue":"6","key":"2025102811214907200_bib33","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"Hemasphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5382\/2418193\/blooda_adv-2024-015014-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5382\/2418193\/blooda_adv-2024-015014-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:22:14Z","timestamp":1761664934000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5382\/546349\/Real-world-outcomes-of-brexucabtagene-autoleucel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":33,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015014","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,28]]}}}